Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes

被引:248
作者
Cheon, HyeonJoo [1 ]
Stark, George R. [1 ]
机构
[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA
关键词
innate immunity; interferon response; STAT1; gene; NF-KAPPA-B; CYCLOOXYGENASE-2; EXPRESSION; TYROSINE PHOSPHORYLATION; NUCLEAR IMPORT; PROTEIN-KINASE; CELLS RESPOND; I INTERFERONS; IFN-GAMMA; ACTIVATION; TRANSCRIPTION;
D O I
10.1073/pnas.0903487106
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
In normal human cells treated with interferons (IFNs), the concentration of tyrosine-phosphorylated STAT1 (YP-STAT1), which drives the expression of a large number of genes, increases quickly but then decreases over a period of several hours. Because the STAT1 gene is activated by YP-STAT1, IFNs stimulate a large increase in the concentration of unphosphorylated STAT1 (U-STAT1) that persists for several days. To test the significance of high U-STAT1 expression, we increased its concentration exogenously in the absence of IFN treatment. In response, the expression of many immune regulatory genes ( e. g., IFI27, IFI44, OAS, and BST2) was increased. In human fibroblasts or mammary epithelial cells treated with low concentrations of IFN-beta or IFN-gamma, the expression of the same genes increased after 6 h and continued to increase after 48 or 72 h, long after the concentration of YP-STAT1 had returned to basal levels. Consistent with its activity as a transcription factor, most U-STAT1 was present in the nuclei of these cells before IFN treatment, and the fraction in nuclei increased 48 h after treatment with IFN. We conclude that the nuclear U-STAT1 that accumulates in response to IFNs maintains or increases the expression of a subset of IFN-induced genes independently of YP-STAT1, and that many of the induced proteins are involved in immune regulation.
引用
收藏
页码:9373 / 9378
页数:6
相关论文
共 28 条
[1]   Bone marrow stromal cell antigen 2 is a specific marker of type IIFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation [J].
Blasius, Amanda L. ;
Giurisato, Emanuele ;
Celia, Marina ;
Schreiber, Robert D. ;
Shaw, Andrey S. ;
Colonna, Marco .
JOURNAL OF IMMUNOLOGY, 2006, 177 (05) :3260-3265
[2]   How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene [J].
Chatterjee-Kishore, M ;
Wright, KL ;
Ting, JPY ;
Stark, GR .
EMBO JOURNAL, 2000, 19 (15) :4111-4122
[3]   Unphosphorylated STAT6 contributes to constitutive cyclooxygenase-2 expression in human non-small cell lung cancer [J].
Cui, X. ;
Zhang, L. ;
Luo, J. ;
Rajasekaran, A. ;
Hazra, S. ;
Cacalano, N. ;
Dubinett, S. M. .
ONCOGENE, 2007, 26 (29) :4253-4260
[4]   Biologic consequences of Stat1-independent IFN signaling [J].
Gil, MP ;
Bohn, E ;
O'Guin, AK ;
Ramana, CV ;
Levine, B ;
Stark, GR ;
Virgin, HW ;
Schreiber, RD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (12) :6680-6685
[5]   Interferon, Mx, and viral countermeasures [J].
Haller, Otto ;
Kochs, Georg ;
Weber, Friedemann .
CYTOKINE & GROWTH FACTOR REVIEWS, 2007, 18 (5-6) :425-433
[6]   STAT1-independent inhibition of cyclooxygenase-2 expression by IFNγ;: a common pathway of IFNγ-mediated gene repression but not gene activation [J].
Klampfer, L. ;
Huang, J. ;
Kaler, P. ;
Sasazuki, T. ;
Shirasawa, S. ;
Augenlicht, L. .
ONCOGENE, 2007, 26 (14) :2071-2081
[7]   Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases [J].
Kumar, A ;
Commane, M ;
Flickinger, TW ;
Horvath, CM ;
Stark, GR .
SCIENCE, 1997, 278 (5343) :1630-1632
[8]   BST-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology [J].
Kupzig, S ;
Korolchuk, V ;
Rollason, R ;
Sugden, A ;
Wilde, A ;
Banting, G .
TRAFFIC, 2003, 4 (10) :694-709
[9]  
Lehtonen A, 1997, J IMMUNOL, V159, P794
[10]   Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy [J].
Lesinski, GB ;
Valentino, D ;
Hade, EM ;
Jones, S ;
Magro, C ;
Chaudhury, AR ;
Walker, MJ ;
Carson, WE .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (09) :815-825